InVivoMAb anti-human CD19

Miltiades P, Lamprianidou E, Kerzeli IK, et al. Three-fold higher frequency of circulating chronic lymphocytic leukemia-like B-cell clones in patients with Ph-Myeloproliferative neoplasms. Leuk Res. 2015,:pii: S0145-2126(15)30357-X. doi: 10.1016/j.leukres.2015.08.004.

Poirot L, Philip B, Schiffer-Mannioui C, et al. Multiplex Genome-Edited T-cell Manufacturing Platform for "Off-the-Shelf" Adoptive T-cell Immunotherapies. Cancer Res. 2015,75(18):3853-64. doi: 10.1158/0008-5472.CAN-14-3321

Smeltzer JP, Jones JM, Ziesmer SC, et al. Pattern of CD14+ follicular dendritic cells and PD1+ T cells independently predicts time to transformation in follicular lymphoma. Clin Cancer Res. 2014,20(11):2862-72. doi: 10.1158/1078-0432.CCR-13-2367

Grada Z, Hegde M, Byrd T, et al. TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy. Mol Ther Nucleic Acids. 2013,2(7):e105. doi: 10.1038/mtna.2013.32

Horton HM, Bernett MJ, Pong E, et al. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 2008,68(19):8049-57. doi: 10.1158/0008-5472.CAN-08-2268

Rosa D, Saletti G, De Gregorio E, et al. Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci U S A. 2005,102(51):18544-9.

Meeker TC, Miller RA, Link MP, et al. A unique human B lymphocyte antigen defined by a monoclonal antibody. Hybridoma. 1984,3(4):305-20.